Betrixaban activates cGAS-STING to promote antitumor immunity without pathological inflammation - PubMed
3 hours ago
- #Cancer Immunotherapy
- #Betrixaban
- #cGAS-STING pathway
- Betrixaban (BT), an FDA-approved Factor Xa inhibitor, acts as a dual immunomodulator that enhances antitumor immune responses and suppresses hyperinflammation.
- BT promotes antitumor immunity by inducing noncanonical, DNA-independent activation of the cGAS-STING pathway, leading to type I interferon signaling without a full inflammatory cascade.
- In mouse tumor models, BT treatment inhibited tumor growth and increased infiltration of activated CD8+ T cells, and its combination with immune checkpoint blockade showed synergistic efficacy.
- BT attenuates pathological inflammation by reducing LPS-induced proinflammatory cytokine production and improving survival in a sepsis model.
- The authors declare no competing interests, and funding sources had no involvement in the study design, data collection, analysis, or decision to publish.